Entrada Therapeutics, Inc. SEC filings TRDA
Entrada Therapeutics, Inc. has 472 filings in SEC EDGAR's recent list, going back to Nov 10, 2016. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 14, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 10, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 19, 2026 | May 18, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 7, 2026 | May 7, 2026 |
| 8-K |
Current report
Results of operations
|
Feb 26, 2026 | Feb 26, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Jan 8, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2025 | Aug 6, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2025 | Jun 11, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 3, 2025 | May 30, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| 8-K |
Current report
Exit or restructuring costs
|
Apr 29, 2025 | Apr 29, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 24, 2025 | Mar 24, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 27, 2025 | Feb 27, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Feb 24, 2025 | Feb 24, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Feb 3, 2025 | Feb 3, 2025 |
| 8-K |
Current report
Results of operations, Other events
|
Jan 15, 2025 | Jan 15, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2024 | Nov 5, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Material agreement, Other events
|
Jun 24, 2024 | Jun 24, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 24, 2024 | Jun 24, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 13, 2024 | Jun 13, 2024 |
| 8-K |
Current report
Results of operations
|
May 7, 2024 | May 7, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 13, 2024 | Mar 13, 2024 |
| 8-K |
Current report
Officer or director change
|
Jan 3, 2024 | Dec 29, 2023 |
| 8-K |
Current report
Officer or director change
|
Dec 6, 2023 | Dec 5, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 22, 2023 | Nov 22, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2023 | Nov 7, 2023 |
| 8-K |
Current report
Material agreement, Other events
|
Nov 1, 2023 | Oct 26, 2023 |
| 8-K |
Current report
Material agreement
|
Sep 29, 2023 | Sep 29, 2023 |
| 8-K |
Current report
Other events
|
Sep 21, 2023 | Sep 21, 2023 |
| 8-K |
Current report
Officer or director change
|
Aug 10, 2023 | Aug 4, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2023 | Aug 8, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 1, 2023 | Aug 1, 2023 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 8, 2023 | Jun 7, 2023 |
| 8-K |
Current report
Results of operations
|
May 10, 2023 | May 10, 2023 |
| 8-K |
Current report
Officer or director change
|
Apr 4, 2023 | Apr 4, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 6, 2023 | Mar 6, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Feb 9, 2023 | Feb 9, 2023 |
| 8-K |
Current report
Other events
|
Jan 9, 2023 | Jan 9, 2023 |
| 8-K |
Current report
Other events
|
Dec 19, 2022 | Dec 19, 2022 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Dec 8, 2022 | Dec 7, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2022 | Nov 7, 2022 |
| 8-K | Current report | Aug 11, 2022 | Aug 11, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 3, 2022 | Jun 2, 2022 |
| 8-K |
Current report
Results of operations
|
May 12, 2022 | May 12, 2022 |
| 8-K |
Current report
Material agreement, New debt
|
Mar 22, 2022 | Mar 16, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 15, 2022 | Mar 15, 2022 |
| 8-K |
Current report
Results of operations
|
Dec 9, 2021 | Dec 9, 2021 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Nov 2, 2021 | Oct 28, 2021 |
Showing 51 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TRDA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1689375
- Former names
- CycloPorters, Inc. (until Nov 10, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.